A novel precision treatment for hard-to-treat cancers

Challenge

Cancer is the second leading cause of death globally, with a strong demand for novel cancer targets and targeted therapies.

Soft tissue sarcoma is a rare type of cancer which accounts for 1% of all adult cancers and 7% of all pediatric cancers.

Gastrointestinal stromal tumour (GIST) is the most common soft tissue sarcoma, with a critical unmet medical need and affecting half a million patients in EU, US, JP, Canada, Australia and China.

GIST - market with critical unmet medical need

Most GIST patients are treated with tyrosine kinase inhibitors (TKIs) to control disease progression, except for wild-type GIST, which does not respond to TKIs and has no treatment available.

Advanced GIST patients develop resistance to TKIs – there is a critical unmet medical need for a GIST therapy beyond TKIs.

Our solution - SAR003

SAR003 stands out by combining advantages of transformative precision medicine innovations with the benefits of being a novel drug product of anagrelide.

SAR003 has a novel mechanism of action as a molecular glue and a novel superior subcutaneous long-acting formulation.

We are developing SAR003 as both monotherapy and combination therapy (with imatinib), with the ultimate goal of providing a curative therapy for advanced GIST and becoming frontline therapy.

Indications

We are first developing SAR003 for the treatment of GIST, where all tumors express the PDE3A gene. We will expand SAR003 therapy development to other PDE3A-expressing cancers.

We are developing a new class of personalised cancer drugs: SAR003 molecular glue in combination with existing anti-cancer agents with other mechanisms of action, based on synergistic effects. These studies are ongoing in pre-clinical stage leading to new IP.